We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Calls for ‘Considered Approach’ in Draft Trial Transparency Policy
EMA Calls for ‘Considered Approach’ in Draft Trial Transparency Policy
July 31, 2013
The European Medicines Agency is seeking feedback on a proposed policy for increasing access to clinical trial data, offering a “considered approach” to transparency that respects patient and commercial interests.